Protara Therapeutics
TARA
15 hedge funds and large institutions have $1.96M invested in Protara Therapeutics in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.
81% more capital inflows, than outflows
Capital inflows: $208K | Capital outflows: $115K
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
7% more funds holding
Funds holding: 14 → 15 (+1)
0.71% more ownership
Funds ownership: 23.27% → 23.98% (+0.71%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$109K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$54.5K |
| 3 |
Wedbush Securities
Los Angeles,
California
|
+$19.9K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$18.6K |
| 5 |
Jane Street
New York
|
+$4.56K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$64.4K |
| 2 |
Two Sigma Securities
New York
|
-$26K |
| 3 |
BlackRock
New York
|
-$14K |
| 4 |
Mariner
Overland Park,
Kansas
|
-$5K |
| 5 |
Morgan Stanley
New York
|
-$4.38K |
TARA Hedge Fund Activity: Q2 2019 in Review
15 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q2 2019, worth a combined $1.96M — down 13% from $2.25M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new TARA positions and 3 closed out — a net gain of 1 holder — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $109K. The largest seller was Vanguard Group, cutting an estimated $64.4K.
- 15 institutional investors held Protara Therapeutics (TARA) as of Q2 2019, up from 14 in Q1 2019.
- Funds reported $1.96M of Protara Therapeutics stock for Q2 2019, down 13% quarter-over-quarter.
- 4 funds opened new Protara Therapeutics positions in Q2 2019 and 3 closed out, a net change of +1 holder.
- The largest Protara Therapeutics buyer in Q2 2019 was Renaissance Technologies, an estimated $109K added.
- The largest Protara Therapeutics seller in Q2 2019 was Vanguard Group, an estimated $64.4K sold.
Based on aggregated 13F filings for Q2 2019.